Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study.

In 30 seconds

This phase II trial evaluated the combination of camrelizumab, apatinib, and intensity-modulated radiotherapy in 44 patients with locally advanced, unresectable hepatocellular carcinoma (HCC). The study found a median progression-free survival of 13.8 months and an objective response rate of 84.1%.

Key findings

• The median progression-free survival was 13.8 months.
• The objective response rate was 84.1%.
• The 24-month progression-free survival rate was 38.1%.
• Grade 3 to 4 treatment-related adverse events occurred in 81.8% of patients.

Why it matters

The findings suggest that combining immune checkpoint inhibitors, TKIs, and radiotherapy may offer a promising treatment strategy for patients with advanced HCC, a population with limited effective options.